|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.08.26 - 13:06
|
Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development (Business Wire)
|
|
|
MIMETAS' unique organ-on-a-chip and human tissue models complement Bruker's multiomics, NMR, spatial biology and preclinical imaging solutionsLEIDEN, The Netherlands--(BUSINESS WIRE)--$BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and advanced human tissue and disease models for drug discovery and development. The investment expands Bruker's post-genomic solutions for disease biology research, as well as for drug discovery and development into Microphysiological Systems (MPS), also referred to as New Approach Methodologies (NAMs), and based on human physiology-relevant model systems.
MIMETAS develops scalable organ-on-a-chip platforms and human tissue models that allow researchers to study disease mechanisms and compound responses in perfused, biologically relevant systems. Its OrganoPlate® platform combines a standard microtiter-plate format with membrane-free microfluidic tissue cultures, supporting imagi...
|
|
|
|
|
|
|
|
|
04.08.26 - 16:01
|
Bruker (BRKR) Q2 Earnings Beat Estimates (Zacks)
|
|
|
Bruker (BRKR) delivered earnings and revenue surprises of +28.95% and -2.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?...
|
|
|
|
|
04.08.26 - 13:06
|
Bruker Reports Second Quarter 2026 Financial Results (Business Wire)
|
|
|
Q2-26 Bruker Scientific Instruments (BSI) bookings up 10% organically year-over-year (yoy), with BSI book-to-bill >1.0x
Q2-26 revenue of $838.5 million, up +5.2% yoy; up 2.8% organically, or +3.4% excluding tariff refunds
Q2-26 GAAP diluted loss per share of $(0.41); non-GAAP diluted earnings per share (EPS) $0.49
Updating FY2026 guidance for currency and tax only:
Revenues of $3.54 to $3.57 billion, up 3% to 4% yoy, with organic growth of 1% to 2%
Non-GAAP EPS of $2.10 to $2.15, up 15% to 17% yoy
BILLERICA, Mass.--(BUSINESS WIRE)--$BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced financial results for the three and six months ended June 30, 2026.
Frank H. Laukien, Bruker's President and CEO, commented: “We returned to organic revenue growth in the second quarter and our Scientific Instruments segment achieved 10% organic bookings growth year-over-year. Our focus on cost and profitability resulted in solid margin expansion and non-GAAP EPS growth in the quarter. In particular, we achieved ...
|
|
|
24.07.26 - 22:06
|
Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast (Business Wire)
|
|
|
BILLERICA, Mass.--(BUSINESS WIRE)--$BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced it will report second quarter 2026 financial results before market opening on Tuesday, August 4, 2026. The Company will host a conference call and webcast at 9:00 a.m. Eastern Daylight Time to discuss the results and current business trends.
To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q2 2026 Earnings Webcast” hyperlink in the “Events & Presentations” section. A slide presentation will be referenced during the webcast and will be posted to the Company's website shortly before the webcast begins.
Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (U.S. toll free) or +1-412-317-6702 (international) and referencing “Bruker's Second Quarter 2026 Earnings Conference Call.”
Bruker is enabling investors to pre-register for the earnings conference call so that they can expedite their entry into the call and avoid the need t...
|
|
|
|
|
15.07.26 - 13:06
|
Bruker Expands Infection Detection Portfolio with Acquisition of Metagenomic mNGS DISQVER® Platform for Pathogenic Microorganisms in Blood (Business Wire)
|
|
|
BREMEN, Germany--(BUSINESS WIRE)--$BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of the DISQVER® clinical metagenomics platform from Noscendo GmbH.DISQVER® enables metagenomic next-generation sequencing (mNGS) analysis of microbes directly from blood samples, further expanding Bruker's NGS-based infection detection capabilities. Without any need for prior cultivation, DISQVER analyzes whole genome sequencing (WGS) data and applies advanced, proprietary bioinformatics to search for more than 11,000 different microbes and parasites. The mNGS analysis can be done directly from cell-free DNA samples from blood, in less than 24 hours after sample receipt. This advanced mNGS clinical research approach can be valuable for bloodstream infections, sepsis, endocarditis, and other severe infectious diseases.Following the acquisition, DISQVER® remains available for research use only, while Bruker is progressing its registration for diagnostic purposes. Financial details of the tran...
|
|
|
|
|
|
|
16.06.26 - 19:03
|
Inszone Insurance Services Acquires Sanford, Bruker & Banks, Inc., Adding Over a Century of Experience to Its Roster (Business Wire)
|
|
|
SACRAMENTO, Calif.--(BUSINESS WIRE)--#agencyacquisition--Inszone Insurance Services, a rapidly growing national provider of commercial, personal, and benefits insurance, is pleased to announce the acquisition of Sanford, Bruker & Banks, Inc., a historic independent insurance agency with roots dating back to 1915.
Founded over a century ago by Davenport Sanford, the agency has spent the last 111 years protecting families and businesses through world events, economic shifts, and massive industry changes. Sanford, Bruker & Banks has stood as a pillar of reliability for generations of clients. Under the leadership of current owner Jeffrey Banks, the agency has continued this incredible legacy, operating as a trusted generalist while developing a strong specialization in serving small and artisan contractors.
At 73 years old, Banks recognized the vital importance of succession planning. He wanted to ensure the agency's long-standing legacy would be protected.
"When you have a business that has been serving th...
|
|
|
09.06.26 - 14:06
|
Quanterix Announces Appointment of Jason Faessler as Chief Financial Officer (Business Wire)
|
|
|
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Jason Faessler as the Company's new Chief Financial Officer, effective June 22. Faessler brings extensive finance leadership experience and expertise in managing complex organizations in the life science tools industry, positioning him to play a pivotal role in executing Quanterix's strategic growth plans in the coming years.
“We are thrilled to welcome Jason to the Quanterix leadership team,” said Everett Cunningham, Chief Executive Officer of Quanterix. “His extensive track record within life science organizations makes him the ideal leader to support our ambitious growth objectives. Jason's expertise in strategic financial and capital planning, operational excellence, and commercial support will be instrumental in advancing our mission.”
Faessler joins Quanterix from Bruker Corporat...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
